ACS
Sanofi diabetes drug fails to show cardio disease benefit
March 19, 2015Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …
German court rules against Lilly in Alimta patent case
March 10, 2015Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed
A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
NICE extends recommendation for Efient
July 24, 2014Sales and Marketing ACS, Efient, NICE, Plavix, longs ton, prasugrel
In updated guidance NICE has extended its recommendation of Efient (prasugrel) in combination with aspirin for preventing blood clots in …
Bayer ‘disappointed’ with FDA
February 18, 2014Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban
Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …
Xarelto gets ACS indication
May 29, 2013Sales and Marketing ACS, Bayer, Xarelto
Bayer HealthCare’s bloodthinner Xarelto has expanded its reach in Europe with approval for secondary prevention after an acute coronary syndrome …
Pharma manufacturing news in brief
February 4, 2013Manufacturing and Production ACS, Amcor, Beanne, Iogen Bio-products, Novozymes, Pluristem
Facility investments from Amcor and Pluristem, Beanne Chemical falls foul of FDA inspectors, Novozymes acquisition plus a green chemistry app.
FDA rejects licence extension for Xarelto
June 26, 2012Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto
The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
Brilique gains NICE approval
October 31, 2011Sales and Marketing ACS, Brilique, NICE, Plavix, clopidogrel
AstraZeneca’s Brilique has been approved by NICE for use in combination with aspirin as an option to treat patients with …
Merck suffers late-stage blow to vorapaxar
January 18, 2011Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar
An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
Apixaban trial for ACS abandoned
October 20, 2010Sales and Marketing ACS, BMS, Pfizer, apixaban
Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
